Advancing Breakthrough Therapies for Cancer
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
First in a New Class of ADCs
The company’s first ADC product ADCETRIS® (brentuximab vedotin) is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. The approval of ADCETRIS makes it the first in a new class of ADCs.
To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings.
Seattle Genetics is jointly developing ADCETRIS in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has full commercialization rights to ADCETRIS in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.
Advancing Our Robust ADC Pipeline
In addition to ADCETRIS, we are advancing a robust ADC product pipeline designed to address the unmet medical needs of people with cancer. Our strong research and development capabilities are our engine for innovation and
long-term growth. Seattle Genetics’ ADC technology is also employed by collaborators and, across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.
Seattle Genetics was founded in 1998 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. We have more than 600 employees throughout the United States, all with a passion for helping people living with cancer.
Improving the lives of people with cancer through innovative and empowered antibody-based therapies
We have built a strong corporate culture around the values of integrity, scientific excellence, teamwork, innovation and mutual respect. Seattle Genetics embodies an entrepreneurial spirit that advances breakthrough therapies, which is why we are an acknowledged leader today in antibody-drug conjugate technology.
Passion for helping patients
Revolutionizing therapy for people living with cancer
Honesty, respect and trust guide us
Premier science empowers our passion
Teamwork & mutual respect
Shared dedication drives successful collaborations
Entrepreneurial spirit advances breakthrough therapies
Great work environment
Commitment and opportunity inspire purposeful contribution
We value integrity, scientific excellence, teamwork, innovation and mutual respect
At Seattle Genetics, we are passionate about positively impacting the lives of people with cancer. Team members bring that enthusiasm to everything we do, striving to attain individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. Put your passion to work at Seattle Genetics.
As a company leading the field in developing antibody-drug conjugates, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground by creating opportunities for focused intellectual curiosity and professional growth. Our state-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping.
Seattle Genetics provides a competitive compensation and benefits package (including stock options, medical, dental, vision, life and disability insurance, employee stock purchase plan and 401(k) plan).
If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards. We want to hear from you!
Living in the Pacific Northwest
With ready access to Puget Sound, lakes and mountains, residents of the Seattle area enjoy skiing, hiking, boating and a world-class trail system for bicycling, running or walking. A robust and diverse cultural scene includes multiple theater, music, dance, art and sports venues, providing access to the best of local, national and international talent. The Pacific Northwest is rich in scientific research and discovery, and home to leading academic and research institutions, including the University of Washington and Fred Hutchinson Cancer Research Center. Proximity to Vancouver, B.C., the San Juan Islands, Portland, Oregon and the Olympic and Cascade Mountains makes it easy to play as hard as you work. At Seattle Genetics, you’ll find a rewarding career in a place you will be proud to call home.
Getting an Interview
Getting an Interview
- Application Details
I applied through a staffing agency. The process took 4+ weeks – interviewed at Seattle Genetics in January 2015.Interview Details
I applied through a recruiter who had already verified references before setting up an interview with the hiring manager. It was obvious from my resume that I have a career gap right from the start. After phone screening by the hiring manager and 3 hour interview with 6 employees the reason for rejection was 'experience not recent'. They wasted my time only to reject me for something they knew long BEFORE multiple rounds of interview. So unprofessional.Interview Questions
No OfferNegative ExperienceAverage Interview
- Quite a few 'Tell me about a time when..." type behavioral questions. Answer Question
Let us know if we're missing any workplace or industry recognition –
To heck with verbs, Seattle Genetics is conjugating antibodies and drugs to fight cancer. The company's technologies use genetically engineered monoclonal antibodies (MAbs, or single source proteins) to trigger cell death in some cancers, but when they can't do it alone, Seattle Genetics pairs them up with drugs using its Antibody-Drug Conjugate (ADC) technology for a one-two punch. Its first product, Adcetris, gained FDA approval in 2011 for treatment of lymphoma in specific patient categories. With partner Millennium Pharmaceuticals, the company is working to expand...